查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1529763

納曲酮和Buprenornhine的全球市場規模、佔有率和趨勢分析：按產品、給藥途徑、應用、分銷管道、地區和細分市場進行預測（2024-2030）

Naltrexone And Buprenorphine Market Size, Share & Trends Analysis Report By Product, By Route of Administration (Oral, Injectable) By Application, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 202 Pages | 商品交期: 2-10個工作天內

價格

納曲酮和Buprenornhine市場成長和趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，全球納曲酮和Buprenornhine市場規模將達到84.2億美元，2024年至2030年複合年成長率為12.41%。推動該市場成長的主要因素是物質使用障礙發生率的上升、政府加強應對危機情況的力度以及對鴉片類藥物使用障礙治療的認知不斷提高。預計這些因素將在預測期內顯著促進該行業的擴張，推動進步並提高成癮護理解決方案的可及性。

《2023 年世界毒品報告》強調了吸毒障礙的全球趨勢，強調鴉片類藥物是過量攝取死亡的主要原因，也是導致殘疾和過早死亡的重要原因。鴉片類藥物使用障礙 (OUD) 影響著全世界數百萬人，而 COVID-19 大流行加劇了治療取得方面的差異。主要濫用藥物存在地區差異，包括歐洲和亞洲的鴉片類藥物、拉丁美洲的可卡因以及東亞和東南亞的甲基安非他命。恥辱和歧視阻礙了治療工作，只有不到 20% 的需要治療的人接受了治療。報告呼籲國際合作應對這些複雜的健康和社會挑戰。

此外，各國政府正在加強以多方面的方式應對 OUD 危機。 2024 年 2 月，經 SAMHSA核准，社區心理健康服務整筆撥款和藥物使用預防、治療和康復服務整筆撥款中的 4660 萬美元分配給了心理健康和藥物使用服務。此外，美國財政部已指定 6,750 萬美元資金用於支持威斯康辛州的這些努力。

此外，產業參與者還透過加強分銷網路、與醫療保健提供者建立策略聯盟以及增加研發投資等策略措施來推動市場成長。例如，2023年7月，Titan Pharmaceuticals, Inc.和Fedson, Inc.簽訂了一項資產購買協議，根據該協議，Titan將出售ProNeura的部分資產。該交易包括一系列藥物成癮治療和其他基於 ProNeura 藥物傳輸技術的早期開發舉措。該公司的藥物成癮產品組合包括納美芬和普布啡植入計畫。此外，Camurus AB 於 2023 年 9 月推出了 Brixadi，這是一種每週一次和每月一次的藥物，含有 Brixadi，適用於治療中度至重度 OUD。這些努力旨在擴大治療的可及性和有效性，並顯著推動進展。

納曲酮和Buprenornhine市場報告亮點

  • 受強大的醫療基礎設施、物質使用障礙的高盛行率以及政府積極支持成癮治療的推動，北美在 2023 年佔據最大的銷售佔有率，達到 39.39%。
  • 按產品分類，Buprenornhine細分市場在 2023 年佔據市場主導地位，佔有率為 70.02%，預計在預測期內將以最快的複合年成長率成長。該行業的成長可歸因於主要企業採取的各種策略，包括產品發布、合作夥伴關係、併購、監管核准、證明療效的臨床試驗以及其他提高治療啟動率的因素。
  • 從給藥途徑來看，2023年口服給藥佔最大佔有率，達55.87%。然而，在Buprenornhine細分市場中，注射給藥佔2023年的大部分佔有率，達65.04%。
  • 以應用程式來看，2023年OUD細分市場佔比為69.03%。納曲酮被廣泛認為可有效治療 OUD，從而在治療方案中廣泛採用。
  • 從通路來看，2023年院內藥局佔比48.26%，佔全球市場主導地位。醫院藥房的成長是由於它們在注射Buprenornhine等 OUD 藥物、確保治療由醫生監督以及促進獲得基本藥物方面發揮關鍵作用。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章納曲酮和Buprenornhine市場變數、趨勢和範圍

  • 納曲酮和Buprenornhine市場陣容展望
    • 母市場展望
    • 配套市場前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 納曲酮和Buprenornhine市場分析工具
    • 波特五力分析
    • PESTLE分析
  • 管道分析
  • 價格分析
  • 選擇植入治療時患者和提供者的考量因素
  • 目標人口分析
  • 納曲酮和Buprenornhine皮下可吸收植入的整體潛在市場 (TAM) 分析

第4章納曲酮和Buprenornhine市場分析：依產品（2018-2030）

  • 納曲酮和Buprenornhine：產品變異性分析
  • 納曲酮和Buprenornhine市場分析：按產品市場
  • 納曲酮
    • 市場收益估算與預測（2018-2030）
  • Buprenornhine
    • 市場收益估算與預測（2018-2030）
    • 貝爾布卡
    • 子位置
    • 賽博松
    • 祖布索爾夫
    • 其他

第5章納曲酮和Buprenornhine市場分析：依給藥途徑（2018-2030）

  • 納曲酮和Buprenornhine：給藥途徑變異分析
  • 納曲酮和Buprenornhine市場分析：按給藥途徑市場
  • 納曲酮
    • 市場收益估算與預測（2018-2030）
    • 口服給藥
    • 注射給藥
    • 植入式給藥
  • Buprenornhine
    • 市場收益估算與預測（2018-2030）
    • 口服給藥
    • 注射給藥
    • 植入式給藥

第6章 納曲酮和Buprenornhine市場分析：依應用分類（2018-2030）

  • 納曲酮和Buprenornhine：使用變化分析
  • 納曲酮和Buprenornhine市場分析：按應用市場
  • 納曲酮
    • 市場收益估算與預測（2018-2030）
    • 鴉片類藥物使用疾患 (OUD)
  • Buprenornhine
    • 市場收益估算與預測（2018-2030）
    • 鴉片類藥物使用疾患 (OUD)

第 7 章 納曲酮與Buprenornhine市場分析：依通路（2018-2030）

  • 納曲酮和Buprenornhine：分銷管道變化分析
  • 納曲酮和Buprenornhine市場分析：按分銷通路市場
  • 醫院藥房
    • 市場收益估算與預測（2018-2030）
  • 零售藥房
    • 市場收益估算與預測（2018-2030）
  • 其他
    • 市場收益估算與預測（2018-2030）

第8章納曲酮和Buprenornhine市場：按產品、給藥途徑、應用和分銷管道分類的區域估計和趨勢分析

  • 納曲酮和Buprenornhine市場：區域展望
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第9章 競爭格局

  • 市場參與企業分類
  • 主要企業簡介
    • Indivior PLC
    • Collegium Pharmaceutical, Inc.（BioDelivery Sciences International, Inc. 的母公司）
    • Alkermes plc
    • Orexo AB
    • Titan Pharmaceuticals, Inc.
    • Omeros Corporation
    • F. Hoffmann-La Roche Ltd.
    • Camurus
    • Sun Pharmaceutical Industries Ltd
    • Braeburn, Inc.
Product Code: GVR-4-68040-342-4

Naltrexone And Buprenorphine Market Growth & Trends:

The global naltrexone and buprenorphine market size is expected to reach USD 8.42 billion by 2030, growing at a CAGR of 12.41% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is experiencing growth primarily due to the rising incidence of substance use disorders, increasing government efforts to address the crisis, and growing awareness of treatments for opioid use disorder. These factors are anticipated to substantially boost industry expansion during the forecast period, fostering advancements and improving accessibility to addiction care solutions.

The World Drug Report 2023 highlights global trends in drug use disorders, emphasizing opioids as the primary cause of death from overdose and significant contributors to years lost due to disability and premature death. Opioid Use Disorder (OUD) affects millions worldwide, with disparities in treatment access exacerbated by the COVID-19 pandemic. Regional variations in primary drugs of abuse include opioids in Europe and Asia, cocaine in Latin America, and methamphetamine in East & Southeast Asia. Stigma and discrimination hinder treatment efforts, with less than 20% of those needing help receiving it. The report calls for international cooperation to address these complex health and societal challenges.

Furthermore, increasing government initiatives to combat the OUD crisis through multifaceted approaches are growing. In February 2024, with the approval of the SAMHSA, USD 46.6 million in supplemental Community Mental Health Services Block Grant and Substance Use Prevention, Treatment, and Recovery Services Block Grant funds have been allocated to mental health and substance use services. In addition, USD 67.5 million from U.S. Department of Treasury funds has been directed to support these efforts in Wisconsin.

Moreover, industry players are driving growth in the market through strategic initiatives, such as enhanced distribution networks, strategic partnerships with healthcare providers, and increased research and development investments. For instance, in July 2023, Titan Pharmaceuticals, Inc. and Fedson, Inc. signed an Asset Purchase Agreement, under which Titan would sell part of ProNeura assets, such as its portfolio of medications for drug addiction and other early development initiatives built on the ProNeura drug delivery technology. The company's addiction portfolio comprised implant programs for Nalmefene and Probuphine. In addition, in September 2023, Camurus AB introduced Brixadi, a weekly and monthly medication containing Brixadi, indicated to treat moderate-to-severe OUD. These efforts aim to expand treatment accessibility and efficacy, propelling advancement significantly.

Naltrexone And Buprenorphine Market Report Highlights:

  • North America accounted for the largest revenue share of 39.39% in 2023, driven by robust healthcare infrastructure, high prevalence of substance use disorder, and proactive government initiatives supporting addiction treatment.
  • Based on product, the buprenorphine segment dominated the market with a share of 70.02% in 2023 and is anticipated to witness the fastest growth at a CAGR over the forecast period. The segment growth can be attributed to the various strategies adopted by key players such as product launches, collaboration, M&A, regulatory approvals, clinical trials proving efficacy, & other factors that enhance treatment initiation rates.
  • Based on route of administration, the oral administration segment held the majority share of 55.87% in 2023. However, in buprenorphine segment, the injectable administration segment held the majority share of 65.04% in 2023.
  • Based on application, the OUD segment dominated the market with a share of 69.03% in 2023. Naltrexone is widely recognized for their efficacy in managing OUD, leading to its extensive adoption in treatment programs.
  • Based on distribution channel, the hospital pharmacies segment dominated the global market with a share of 48.26% in 2023. Growth can be attributed to their key role in administering parenteral OUD treatments, such as buprenorphine, ensuring physician-supervised care, and facilitating access to essential medications.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Route of Administration
    • 1.2.3. Application
    • 1.2.4. Distribution channel
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Product and Route of Administration Segment Snapshot
  • 2.3. Application and Distribution Channel Segment Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Naltrexone and Buprenorphine Market Variables, Trends, and Scope

  • 3.1. Naltrexone and Buprenorphine Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing prevalence of substance use disorders
      • 3.2.1.2. Growing government initiatives to combat the crisis
      • 3.2.1.3. Increasing awareness of opioid use disorder treatment
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost of treatment
      • 3.2.2.2. Retention and adherence challenges
  • 3.3. Naltrexone and Buprenorphine Market Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTLE Analysis
  • 3.4. Pipeline Analysis
  • 3.5. Pricing Analysis
  • 3.6. Patient and Provider Considerations in Choosing Implantable Treatments
  • 3.7. Target Population Analysis
  • 3.8. Total Addressable Market (TAM) Analysis for Naltrexone & Buprenorphine Subcutaneous Absorbable Implants

Chapter 4. Naltrexone and Buprenorphine Market Analysis, by Product, 2018 - 2030 (USD Million)

  • 4.1. Naltrexone and Buprenorphine: Product Movement Analysis
  • 4.2. Naltrexone and Buprenorphine Market Analysis, by Product Market (USD Million)
  • 4.3. Naltrexone
    • 4.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Buprenorphine
    • 4.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.2. BELBUCA
      • 4.4.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.3. Sublocade
      • 4.4.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.4. Suboxone
      • 4.4.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.5. Zubsolv
      • 4.4.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.6. Others
      • 4.4.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Naltrexone and Buprenorphine Market Analysis, by Route of Administration, 2018 - 2030 (USD Million)

  • 5.1. Naltrexone and Buprenorphine: Route of Administration Movement Analysis
  • 5.2. Naltrexone and Buprenorphine Market Analysis, by Route of Administration Market (USD Million)
  • 5.3. Naltrexone
    • 5.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2. Oral Administration
      • 5.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.3. Injectable Administration
      • 5.3.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.4. Implantable Administration
      • 5.3.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Buprenorphine
    • 5.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.2. Oral Administration
      • 5.4.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.3. Injectable Administration
      • 5.4.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.4. Implantable Administration
      • 5.4.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Naltrexone and Buprenorphine Market Analysis, by Application, 2018 - 2030 (USD Million)

  • 6.1. Naltrexone and Buprenorphine: Application Movement Analysis
  • 6.2. Naltrexone and Buprenorphine Market Analysis, by Application Market (USD Million)
  • 6.3. Naltrexone
    • 6.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. Opioid use disorder (OUD)
      • 6.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.3.2.2. Alcohol use disorder (AUD)
      • 6.3.2.3. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Buprenorphine
    • 6.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. Opioid use disorder (OUD)
      • 6.4.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Naltrexone and Buprenorphine Market Analysis, by Distribution Channel, 2018 - 2030 (USD Million)

  • 7.1. Naltrexone and Buprenorphine: Distribution Channel Movement Analysis
  • 7.2. Naltrexone and Buprenorphine Market Analysis, by Distribution Channel Market (USD Million)
  • 7.3. Hospital Pharmacies
    • 7.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Retail Pharmacies
    • 7.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Others
    • 7.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Naltrexone and Buprenorphine Market: Regional Estimates and Trend Analysis by Product, by Route of Administration, by Application, by Distribution Channel

  • 8.1. Naltrexone and Buprenorphine Market: Regional Outlook
  • 8.2. North America
    • 8.2.1. North America Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. Key Country Dynamics
      • 8.2.2.2. U.S. Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.2.2.3. Competitive/Market Scenario
      • 8.2.2.4. Regulatory Framework
      • 8.2.2.5. Reimbursement scenario
    • 8.2.3. Canada
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Canada Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.2.3.3. Competitive/Market Scenario
      • 8.2.3.4. Regulatory Framework
      • 8.2.3.5. Reimbursement Scenario
    • 8.2.4. Mexico
      • 8.2.4.1. Key Country Dynamics
      • 8.2.4.2. Mexico Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.2.4.3. Competitive/Market Scenario
      • 8.2.4.4. Regulatory Framework
      • 8.2.4.5. Reimbursement Scenario
  • 8.3. Europe
    • 8.3.1. Europe Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.2. UK
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. UK Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.3.2.3. Competitive/Market Scenario
      • 8.3.2.4. Regulatory Framework
      • 8.3.2.5. Reimbursement Scenario
    • 8.3.3. Germany
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Germany Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.3.3.3. Competitive/Market Scenario
      • 8.3.3.4. Regulatory Framework
      • 8.3.3.5. Reimbursement Scenario
    • 8.3.4. France
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. France Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.3.4.3. Competitive/Market Scenario
      • 8.3.4.4. Regulatory Framework
      • 8.3.4.5. Reimbursement Scenario
    • 8.3.5. Spain
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Spain Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.3.5.3. Competitive/Market Scenario
      • 8.3.5.4. Regulatory Framework
      • 8.3.5.5. Reimbursement Scenario
    • 8.3.6. Italy
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Italy Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.3.6.3. Competitive/Market Scenario
      • 8.3.6.4. Regulatory Framework
      • 8.3.6.5. Reimbursement Scenario
    • 8.3.7. Denmark
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Denmark Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.3.7.3. Competitive/Market Scenario
      • 8.3.7.4. Regulatory Framework
      • 8.3.7.5. Reimbursement Scenario
    • 8.3.8. Sweden
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Sweden Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.3.8.3. Competitive/Market Scenario
      • 8.3.8.4. Regulatory Framework
      • 8.3.8.5. Reimbursement Scenario
    • 8.3.9. 6.3.9 Norway
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Norway Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.3.9.3. Competitive/Market Scenario
      • 8.3.9.4. Regulatory Framework
      • 8.3.9.5. Reimbursement Scenario
      • 8.3.9.6. Rest of Europe Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Naltrexone and Buprenorphine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Japan Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.4.2.3. Competitive/Market Scenario
      • 8.4.2.4. Regulatory Framework
      • 8.4.2.5. Reimbursement Scenario
    • 8.4.3. China
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. China Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.4.3.3. Competitive/Market Scenario
      • 8.4.3.4. Regulatory Framework
      • 8.4.3.5. Reimbursement Scenario
    • 8.4.4. India
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. India Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.4.4.3. Competitive/Market Scenario
      • 8.4.4.4. Regulatory Framework
      • 8.4.4.5. Reimbursement Scenario
    • 8.4.5. Australia
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Australia Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.4.5.3. Competitive/Market Scenario
      • 8.4.5.4. Regulatory Framework
      • 8.4.5.5. Reimbursement Scenario
    • 8.4.6. Thailand
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Thailand Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.4.6.3. Competitive/Market Scenario
      • 8.4.6.4. Regulatory Framework
      • 8.4.6.5. Reimbursement Scenario
    • 8.4.7. South Korea
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. South Korea Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.4.7.3. Competitive/Market Scenario
      • 8.4.7.4. Regulatory Framework
      • 8.4.7.5. Reimbursement Scenario
      • 8.4.7.6. Rest of Asia Pacific Naltrexone and Buprenorphine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Brazil Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.5.2.3. Competitive/Market Scenario
      • 8.5.2.4. Regulatory Framework
      • 8.5.2.5. Reimbursement Scenario
    • 8.5.3. Argentina
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Argentina Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.5.3.3. Competitive/Market Scenario
      • 8.5.3.4. Regulatory Framework
      • 8.5.3.5. Reimbursement Scenario
      • 8.5.3.6. Rest of Latin America Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. 6.6 MEA
    • 8.6.1. MEA Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. South Africa Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.6.2.3. Competitive/Market Scenario
      • 8.6.2.4. Regulatory Framework
      • 8.6.2.5. Reimbursement Scenario
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Saudi Arabia Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.6.3.3. Competitive/Market Scenario
      • 8.6.3.4. Regulatory Framework
      • 8.6.3.5. Reimbursement Scenario
    • 8.6.4. UAE
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. UAE Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.6.4.3. Competitive/Market Scenario
      • 8.6.4.4. Regulatory Framework
      • 8.6.4.5. Reimbursement Scenario
    • 8.6.5. Kuwait
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Kuwait Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.6.5.3. Competitive/Market Scenario
      • 8.6.5.4. Regulatory Framework
      • 8.6.5.5. Reimbursement Scenario
    • 8.6.6. Rest of MEA Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
  • 9.2. Key Company Profiles
    • 9.2.1. Indivior PLC
      • 9.2.1.1. Company overview
      • 9.2.1.2. Financial performance
      • 9.2.1.3. Product benchmarking
      • 9.2.1.4. Strategic initiatives
    • 9.2.2. Collegium Pharmaceutical, Inc. (Parent company of BioDelivery Sciences International, Inc.)
      • 9.2.2.1. Company overview
      • 9.2.2.2. Financial performance
      • 9.2.2.3. Product benchmarking
      • 9.2.2.4. Strategic initiatives
    • 9.2.3. Alkermes plc
      • 9.2.3.1. Company overview
      • 9.2.3.2. Financial performance
      • 9.2.3.3. Product benchmarking
      • 9.2.3.4. Strategic initiatives
    • 9.2.4. Orexo AB
      • 9.2.4.1. Company overview
      • 9.2.4.2. Financial performance
      • 9.2.4.3. Product benchmarking
      • 9.2.4.4. Strategic initiatives
    • 9.2.5. Titan Pharmaceuticals, Inc.
      • 9.2.5.1. Company overview
      • 9.2.5.2. Financial performance
      • 9.2.5.3. Product benchmarking
      • 9.2.5.4. Strategic initiatives
    • 9.2.6. Omeros Corporation
      • 9.2.6.1. Company overview
      • 9.2.6.2. Financial performance
      • 9.2.6.3. Product benchmarking
      • 9.2.6.4. Strategic initiatives
    • 9.2.7. F. Hoffmann-La Roche Ltd.
      • 9.2.7.1. Company overview
      • 9.2.7.2. Financial performance
      • 9.2.7.3. Product benchmarking
      • 9.2.7.4. Strategic initiatives
    • 9.2.8. Camurus
      • 9.2.8.1. Company overview
      • 9.2.8.2. Financial performance
      • 9.2.8.3. Product benchmarking
      • 9.2.8.4. Strategic initiatives
    • 9.2.9. Sun Pharmaceutical Industries Ltd
      • 9.2.9.1. Company overview
      • 9.2.9.2. Financial performance
      • 9.2.9.3. Product benchmarking
      • 9.2.9.4. Strategic initiatives
    • 9.2.10. Braeburn, Inc.
      • 9.2.10.1. Company overview
      • 9.2.10.2. Financial performance
      • 9.2.10.3. Product benchmarking
      • 9.2.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 4 Global naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 5 Global naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 6 Global naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 7 North America naltrexone and buprenorphine market, by region, 2018 - 2030 (USD Million)
  • Table 8 North America naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 9 North America naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 10 North America naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 11 North America naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 12 U.S. naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 13 U.S. naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 14 U.S. naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 15 U.S. naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 16 Canada naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 17 Canada naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 18 Canada naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 19 Canada naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20 Mexico naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 21 Mexico naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 22 Mexico naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 23 Mexico naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24 Europe naltrexone and buprenorphine market, by country, 2018 - 2030 (USD Million)
  • Table 25 Europe naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 26 Europe naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 27 Europe naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 28 Europe naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 29 UK naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 30 UK naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 31 UK naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 32 UK naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 33 Germany naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 34 Germany naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 35 Germany naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 36 Germany naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37 France naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 38 France naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 39 France naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 40 France naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 41 Italy naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 42 Italy naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 43 Italy naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 44 Italy naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45 Spain naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 46 Spain naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 47 Spain naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 48 Spain naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 49 Norway naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 50 Norway naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 51 Norway naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 52 Norway naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 53 Sweden naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 54 Sweden naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 55 Sweden naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 56 Sweden naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 57 Denmark naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 58 Denmark naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 59 Denmark naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 60 Denmark naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61 Asia Pacific naltrexone and buprenorphine market, by country, 2018 - 2030 (USD Million)
  • Table 62 Asia Pacific naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 63 Asia Pacific naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 64 Asia Pacific naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 65 Asia Pacific naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 66 Japan naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 67 Japan naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 68 Japan naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 69 Japan naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 70 China naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 71 China naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 72 China naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 73 China naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 74 India naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 75 India naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 76 India naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 77 India naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 78 Australia naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 79 Australia naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 80 Australia naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 81 Australia naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 82 South Korea naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 83 South Korea naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 84 South Korea naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 85 South Korea naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 86 Thailand naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 87 Thailand naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 88 Thailand naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 89 Thailand naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 90 Latin America naltrexone and buprenorphine market, by country, 2018 - 2030 (USD Million)
  • Table 91 Latin America naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 92 Latin America naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 93 Latin America naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 94 Latin America naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 95 Brazil naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 96 Brazil naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 97 Brazil naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 98 Brazil naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 99 Argentina naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 100 Argentina naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 101 Argentina naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 102 Argentina naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 103 Middle East & Africa naltrexone and buprenorphine market, by country, 2018 - 2030 (USD Million)
  • Table 104 Middle East & Africa naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 105 Middle East & Africa naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 106 Middle East & Africa naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 107 Middle East & Africa naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 108 South Africa naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 109 South Africa naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 110 South Africa naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 111 South Africa naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 112 Saudi Arabia naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 114 Saudi Arabia naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 115 Saudi Arabia naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 116 UAE naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 117 UAE naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 118 UAE naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 119 UAE naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 120 Kuwait naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
  • Table 121 Kuwait naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 122 Kuwait naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
  • Table 123 Kuwait naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)

List of Fig.ures

Fig. 1 Naltrexone and buprenorphine market segmentation

Fig. 2 Market research process

Fig. 3 Data triangulation techniques

Fig. 4 Primary research pattern

Fig. 5 Market research approaches

Fig. 6 Value chain-based sizing & forecasting

Fig. 7 QFD modelling for market share assessment

Fig. 8 Market formulation & validation

Fig. 9 Market snapshot

Fig. 10 Molecule and sales channel segment snapshot

Fig. 11 Competitive landscape snapshot

Fig. 12 Global Pharmaceutical Market, (USD billion)

Fig. 13 Market dynamics

Fig. 14 Porter's five forces analysis

Fig. 15 PESTLE analysis

Fig. 16 Naltrexone and buprenorphine: Product outlook and key takeaways

Fig. 17 Naltrexone and buprenorphine market: Product market movement analysis

Fig. 18 Naltrexone market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 19 Buprenorphine market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 20 BELBUCA market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 21 Sublocade market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 22 Suboxone market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 23 Zubsolv market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 24 Others market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 25 Naltrexone and buprenorphine: Route of administration outlook and key takeaways

Fig. 26 Naltrexone and buprenorphine market: Route of administration market movement analysis

Fig. 27 Naltrexone market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 28 Oral administration market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 29 Injectable administration market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 30 Implantable administration market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 31 Buprenorphine market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 32 Oral administration market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 33 Injectable administration market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 34 Implantable administration market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 35 Naltrexone and buprenorphine: Application outlook and key takeaways

Fig. 36 Naltrexone and buprenorphine market: Application market movement analysis

Fig. 37 Naltrexone market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 38 Opioid Use Disorder (OUD) market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 39 Alcohol use disorder (AUD) market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 40 Buprenorphine market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 41 Opioid Use Disorder (OUD) market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 42 Naltrexone and buprenorphine: Distribution channel outlook and key takeaways

Fig. 43 Naltrexone and buprenorphine market: Distribution channel market movement analysis

Fig. 44 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 45 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 46 Other market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 47 Naltrexone and buprenorphine market revenue, by region, 2023 & 2030, USD Million

Fig. 48 Regional marketplace: Key takeaways

Fig. 49 Regional marketplace: Key takeaways

Fig. 50 North America naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 51 Key country dynamics

Fig. 52 U.S. naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 53 Key country dynamics

Fig. 54 Canada naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 55 Key country dynamics

Fig. 56 Mexico naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 57 Regulatory framework

Fig. 58 Europe naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 59 Key country dynamics

Fig. 60 UK naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 61 Key country dynamics

Fig. 62 Germany naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 63 Key country dynamics

Fig. 64 France naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 65 Key country dynamics

Fig. 66 Spain naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 67 Key country dynamics

Fig. 68 Italy naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 69 Key country dynamics

Fig. 70 Denmark naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 71 Key country dynamics

Fig. 72 Sweden naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 73 Key country dynamics

Fig. 74 Norway naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 75 Rest of Europe naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 76 Asia Pacific naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 77 Key country dynamics

Fig. 78 Japan naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 79 Key country dynamics

Fig. 80 China naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 81 China regulatory details

Fig. 82 India naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 83 Key country dynamics

Fig. 84 Australia naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 85 Key country dynamics

Fig. 86 Thailand naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 87 Key country dynamics

Fig. 88 South Korea naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 89 Rest of Asia Pacific naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 90 Latin America naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 91 Key country dynamics

Fig. 92 Brazil naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 93 Brazil regulation details

Fig. 94 Key country dynamics

Fig. 95 Argentina naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 96 Argentina regulatory framework

Fig. 97 Rest of Latin America naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 98 Key country dynamics

Fig. 99 South Africa naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 100 Key country dynamics

Fig. 101 Saudi Arabia naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 102 Key country dynamics

Fig. 103 UAE naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 104 Key country dynamics

Fig. 105 Kuwait naltrexone and buprenorphine market estimates and forecasts, 2018

Fig. 106 Rest of MEA naltrexone and buprenorphine market estimates and forecasts,

Fig. 107 Company/competition categorization

Fig. 108 Company market share analysis, 2023

Fig. 109 Strategy mapping